Presentation: Thomas Muster

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

please check before submitting

Mobile number:

What is your role?

Subscribe to VaccineNation Newsletter?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

The necessity of preparation for a potential new influenza pandemic remains a widely debated issue among experts in the Vaccines industry. Worldwide ongoing influenza research continues to find better ways to prevent, diagnose, and treat seasonal and pandemic influenza.

Dr. Thomas Muster, the CEO/CSO and co-founder of AVIR Green Hills Biotechnology, joined us at the World Influenza Congress in December 2011 as a speaker to share innovations in Virology, in particular with the deltaFLU®, a replication-deficient intranasal influenza vaccine.

Why not download full details of his presentation and discover how to optimise the process for an attenuated influenza vaccine produced on vero cells:
• High yield production in Vero cells
• Induces mucosal and systemic immunity
• Rapid generation of vaccine virus
• Clinical trial results

Presentation: Thomas Muster

information we require

please check before submitting